Taseko Proposes Name Change To Trekor Metals Limited at Upcoming Annual General Meeting

Freehold Royalties Says Received TSX Approval for Renewal of Normal Course Issuer Bid

Redwood AI Collaborates with Resilience Biosciences For AI-Assisted Small-Molecule Drug Development

Redwood AI (AIRX.CN) is collaborating with Resilience Biosciences to help develop AI-assisted computational chemistry workflows for small-molecule drug development, the company said over the weekend.Resilience will use Redwood's AI platform to explore new drug-like molecules more efficiently, to identify "useful" chemical designs, a statement said."Small-molecule development requires a careful balance of creativity, scientific rigour, synthetic feasibility, and intellectual property awareness. Our goal is to give research teams better tools to explore chemical possibilities in a structured, secure, and scalable way," said Redwood chief executive Louis Dron."This collaboration demonstrates how AI can be applied to practical, IP-aware chemistry workflows that support a more efficient path from early molecular ideas to development-ready opportunities," he added.

George Weston Renews NCIB

George Weston (WN.TO) is renewing its normal course issuer bid (NCIB), and may buy back up to 18.8 million shares, the company said on Monday.The NCIB will run from May 27 for one year.Under its prior share buyback, which terminates on May 26, George Weston bought back 11.4 million shares at a weighted average price of $92.95.George Weston shares closed down $0.37, to $96.46 on Friday, on the Toronto Stock Exchange.